Short Summary
The USPTO Office Director denied institution of inter partes review (IPR2025-01127) for the challenged patent, meaning no trial will proceed on the claims.
Detailed Summary
This notice confirms that the Office Director has denied institution of inter partes review (IPR) across several proceedings, including IPR2025-01127. The denial was made pursuant to 35 U.S.C. § 314(a), and therefore, no trial will be instituted in these matters.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Aerin Medical Inc. vs Neurent Medical Ltd. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Imperative Care, Inc.vsInari Medical, Inc. et al.
Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.
Samsung Electronics Co., Ltd. et al.vsOne-E-Way, Inc.
The USPTO granted institution for IPR2025-01541 after determining the petitioner had a reasonable likelihood of prevailing. This decision moves the case forward to merits review.
SAMSUNG ELECTRONICS CO., LTD. et al.vsiCashe, Inc.
Samsung seeks Director Review of a USPTO discretionary denial of its IPRs against iCashe’s patent. iCashe argues the Director acted properly under established memos and statutes, and that Samsung’s due‑process claims fail. The patent owner requests denial of the review.
Apple Inc.vsHBCU Messaging US LP
Apple has filed a Request for Director Review seeking to overturn a PTAB decision that denied institution of its IPR against HBCU Messaging’s MMS patent. The petitioner argues that its claim‑construction positions are consistent with district‑court rulings and that the Board improperly applied the Revvo discretionary denial. Apple asks that the decision be vacated and the case be instituted on the merits.
Apple Inc.vsImberaTek, LLC
Apple and patent holder ImberaTek have settled their dispute over patent 7,989,944 and jointly moved to terminate the pending IPR. The motion relies on good‑cause authority to dismiss the pre‑institution proceeding.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.